What MOTS-c is. And where it comes from
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a 16-amino-acid peptide encoded in the mitochondrial genome. It was discovered in 2015 by Changhan David Lee's lab at the University of Southern California. Unlike most peptides your body uses, MOTS-c does not come from nuclear DNA, it comes from the small circular genome inside your mitochondria.
This makes it part of a small family called mitochondrial-derived peptides (MDPs), which also includes Humanin. These peptides appear to act as retrograde signals, messages from mitochondria back to the cell nucleus, communicating about metabolic status and cellular stress.
MOTS-c is one of the few peptides that originate from mitochondrial DNA. That alone makes it scientifically interesting, it suggests mitochondria are not just energy factories but active signaling participants in metabolic regulation.
Mechanism, in plain English
The published literature identifies several metabolic pathways influenced by MOTS-c in animal models.
Want all 32 Anti-Aging & Longevity compounds in one place?
The Peptexa Anti-Aging & Longevity guide covers every compound in this category, mechanism, evidence level, and FDA status for each.
What the evidence shows
The bulk of the evidence for MOTS-c comes from animal models. In mice, MOTS-c has been shown to prevent age-related insulin resistance, improve exercise capacity, and protect against diet-induced obesity. The landmark paper is Lee et al. (2015) in Cell Metabolism.
In humans, early observational data suggests circulating MOTS-c levels decline with age and correlate with metabolic health markers. A small interventional study has been reported but data is preliminary. The compound remains in early research stages.
The evidence level is ★★☆☆☆, primarily preclinical. The animal signal is strong but human clinical proof is not established.
Strong animal data does not equal human clinical proof. MOTS-c is a compelling research compound, but anyone claiming it is a proven exercise replacement or metabolic therapy is ahead of the science.
FDA status
MOTS-c is not FDA-approved for any human indication. It is a research compound.
No clinical trials for MOTS-c are currently registered on ClinicalTrials.gov for metabolic or anti-aging indications. Last reviewed 2026-08-19.
Common synonyms researchers use
MOTS-c · Mitochondrial ORF of the Twelve S rRNA Type-c · Mitochondrial-derived peptide · MDP
Safety & adverse-event landscape
In published animal studies, MOTS-c has been administered without reported mortality or significant adverse events. Human safety data is extremely limited.
As a metabolic regulator that influences insulin sensitivity and AMPK activation, theoretical interactions with diabetes medications and metabolic drugs should be considered. There is no established human safety profile.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving a peptide or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Anti-Aging & Longevity reference
32 compounds. Mechanism, evidence level, and regulatory status for every one.
Get the Anti-Aging & Longevity Guide →